Palvella Therapeutics (PVLA) to Release Earnings on Tuesday

Palvella Therapeutics (NASDAQ:PVLA) is expected to be announcing its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.95) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 8:30 AM ET.

Palvella Therapeutics Stock Down 4.5%

PVLA stock opened at $112.37 on Friday. Palvella Therapeutics has a twelve month low of $18.23 and a twelve month high of $151.18. The company has a market cap of $1.33 billion, a PE ratio of -42.73 and a beta of -0.30. The business’s 50-day simple moving average is $104.52 and its 200 day simple moving average is $90.58.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PVLA shares. Mizuho boosted their price target on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group boosted their price objective on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Stifel Nicolaus set a $250.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. HC Wainwright increased their price target on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $195.93.

Insider Buying and Selling

In related news, Director George M. Jenkins acquired 4,000 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were bought at an average cost of $125.00 per share, with a total value of $500,000.00. Following the completion of the transaction, the director directly owned 187,171 shares of the company’s stock, valued at $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PVLA. Virtus Investment Advisers LLC bought a new position in shares of Palvella Therapeutics in the 4th quarter worth $282,000. JPMorgan Chase & Co. boosted its holdings in Palvella Therapeutics by 33.7% during the third quarter. JPMorgan Chase & Co. now owns 4,338 shares of the company’s stock worth $272,000 after purchasing an additional 1,093 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Palvella Therapeutics in the 3rd quarter worth approximately $259,000. Two Sigma Investments LP purchased a new position in Palvella Therapeutics in the third quarter worth $256,000. Finally, The Manufacturers Life Insurance Company bought a new position in Palvella Therapeutics during the fourth quarter valued at about $238,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.